FDA ApprovalOLC's FDA approval is expected by its PDUFA date, affirming a buy recommendation.
Market OpportunityOLC's potential to attain pricing similar to the leading branded drug in the category, Fosrenol, suggests a significant market opportunity.
Patient SatisfactionHigh patient satisfaction with OLC is shown, with 98% of patients finding it easy to take and 89% expressing satisfaction.